Viewing StudyNCT02736448

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 8:26 AM
Last Modification Date: 2024-10-26 @ 12:00 PM
Study NCT ID: NCT02736448
Status: UNKNOWN
Last Update Posted: 2021-02-26
First Post: 2016-04-07
Brief Title: 177Lutethium - Peptide Receptor Radionuclide Therapy Lu-PRRT Plus Capecitabine Versus Lu-PRRT in FDG Positive Gastro-entero-pancreatic Neuroendocrine Tumors
Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Organization: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Gastro-entero-pancreatic Neuroendocrine Tumors
Keywords:
Name View
low dose of capecitabine View
GEP-NET tumors View
Lu-PRRT View
177Lutethium - Peptide Receptor Radionuclide Therapy View
gastro-entero-pancreatic neuroendocrine tumors View
18-FDG Positron Emission Tomography PET positive View